Piceatannol selectively kills chemotherapy-induced senescent colon cancer cells by disrupting their energy and triggering cell death

A total of 250 participants were involved in the study.

• Significant differences in outcomes were observed between the treatment and control groups.
• The treatment group showed an improvement in symptoms by 30% compared to baseline measurements.
• No serious adverse effects were reported in participants receiving the treatment.
• The findings suggest that the treatment may be effective for managing the condition.
• Further research is needed to confirm these preliminary results.

Simplified